Tier 2 — strong

Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study

Noriyuki Kanzaki, Kayo Saito, Akifumi Maeda, Yoshinori Kitagawa, Yoshinobu Kiso, Keita Watanabe, Akihito Tomonaga, Isao Nagaoka, Hideyo Yamaguchi
Journal of the science of food and agriculture 2012 92(4):862

Bibliography

PubMed
PMID 21969261
DOI
10.1002/jsfa.4660
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample40 Japanese adults with symptomatic knee osteoarthritis
InterventionGlucosamine hydrochloride 1,200 mg, chondroitin sulfate 60 mg, and quercetin glycosides 45 mg/day
Duration16 weeks
EndpointsSymptoms and quality of life; Bone or cartilage measures

What the study showed, in plain terms

Published in 2012, this source examined bone and joint health. Design: Randomized double-blind placebo-controlled trial. Sample/model: 40 Japanese adults with symptomatic knee osteoarthritis. The exposure or intervention was Glucosamine hydrochloride 1,200 mg, chondroitin sulfate 60 mg, and quercetin glycosides 45 mg/day. Follow-up or treatment period: 16 weeks.

The combination improved selected symptom and function scores. A cartilage biomarker result was a trend rather than definitive evidence of structural benefit.

Three active ingredients prevent attribution to quercetin. The trial does not establish slower disease progression or cartilage regeneration.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The combination improved selected symptom and function scores.
  • A cartilage biomarker result was a trend rather than definitive evidence of structural benefit.
  • The recorded outcome domains were Symptoms and quality of life; Bone or cartilage measures.
  • The result applies to the tested exposure: Glucosamine hydrochloride 1,200 mg, chondroitin sulfate 60 mg, and quercetin glycosides 45 mg/day; 16 weeks.

What this study can and cannot tell us

  • Three active ingredients prevent attribution to quercetin. The trial does not establish slower disease progression or cartilage regeneration.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Effects of an oral administration of glucosamine-chondroitin-quercetin glucoside on the synovial fluid properties in patients with osteoarthritis and rheumatoid arthritis
Hiroaki Matsuno et al. · Bioscience, biotechnology, and biochemistry · 2009

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology